nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP2A6—esophageal cancer	0.502	0.729	CbGaD
Azelastine—ABCB1—esophageal cancer	0.187	0.271	CbGaD
Azelastine—CYP2C9—Capecitabine—esophageal cancer	0.0263	0.306	CbGbCtD
Azelastine—CYP2B6—Cisplatin—esophageal cancer	0.025	0.292	CbGbCtD
Azelastine—CYP2C9—Cisplatin—esophageal cancer	0.0132	0.154	CbGbCtD
Azelastine—ABCB1—Cisplatin—esophageal cancer	0.0128	0.15	CbGbCtD
Azelastine—Mucosal ulceration—Capecitabine—esophageal cancer	0.00953	0.136	CcSEcCtD
Azelastine—ABCB1—Methotrexate—esophageal cancer	0.00834	0.0972	CbGbCtD
Azelastine—Dysaesthesia—Capecitabine—esophageal cancer	0.00159	0.0226	CcSEcCtD
Azelastine—Mucosal inflammation—Capecitabine—esophageal cancer	0.00124	0.0177	CcSEcCtD
Azelastine—Sneezing—Capecitabine—esophageal cancer	0.00124	0.0177	CcSEcCtD
Azelastine—Furunculosis—Methotrexate—esophageal cancer	0.0012	0.0171	CcSEcCtD
Azelastine—Ageusia—Cisplatin—esophageal cancer	0.00115	0.0164	CcSEcCtD
Azelastine—Infection—Carboplatin—esophageal cancer	0.00112	0.016	CcSEcCtD
Azelastine—Ulcerative stomatitis—Methotrexate—esophageal cancer	0.00111	0.0158	CcSEcCtD
Azelastine—Furuncle—Methotrexate—esophageal cancer	0.00104	0.0149	CcSEcCtD
Azelastine—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00102	0.0145	CcSEcCtD
Azelastine—Laryngeal pain—Capecitabine—esophageal cancer	0.00101	0.0144	CcSEcCtD
Azelastine—Ulcer—Cisplatin—esophageal cancer	0.000984	0.014	CcSEcCtD
Azelastine—Pain—Carboplatin—esophageal cancer	0.000968	0.0138	CcSEcCtD
Azelastine—Laryngitis—Capecitabine—esophageal cancer	0.000952	0.0136	CcSEcCtD
Azelastine—Mucosal inflammation—Methotrexate—esophageal cancer	0.000923	0.0132	CcSEcCtD
Azelastine—Body temperature increased—Carboplatin—esophageal cancer	0.000895	0.0128	CcSEcCtD
Azelastine—Ageusia—Capecitabine—esophageal cancer	0.000847	0.0121	CcSEcCtD
Azelastine—Lacrimation increased—Capecitabine—esophageal cancer	0.000745	0.0106	CcSEcCtD
Azelastine—Herpes simplex—Capecitabine—esophageal cancer	0.000745	0.0106	CcSEcCtD
Azelastine—Ulcer—Capecitabine—esophageal cancer	0.000725	0.0103	CcSEcCtD
Azelastine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000698	0.00996	CcSEcCtD
Azelastine—Influenza like illness—Capecitabine—esophageal cancer	0.000666	0.0095	CcSEcCtD
Azelastine—Face oedema—Cisplatin—esophageal cancer	0.000652	0.0093	CcSEcCtD
Azelastine—Mouth ulceration—Capecitabine—esophageal cancer	0.00062	0.00885	CcSEcCtD
Azelastine—Nasopharyngitis—Cisplatin—esophageal cancer	0.000604	0.00862	CcSEcCtD
Azelastine—Abnormal vision—Capecitabine—esophageal cancer	0.000598	0.00854	CcSEcCtD
Azelastine—Mental disability—Capecitabine—esophageal cancer	0.000595	0.00849	CcSEcCtD
Azelastine—Sleep disorder—Capecitabine—esophageal cancer	0.000575	0.00821	CcSEcCtD
Azelastine—Gastroenteritis—Capecitabine—esophageal cancer	0.000562	0.00802	CcSEcCtD
Azelastine—Glossitis—Methotrexate—esophageal cancer	0.000554	0.00791	CcSEcCtD
Azelastine—Herpes simplex—Methotrexate—esophageal cancer	0.000554	0.00791	CcSEcCtD
Azelastine—Eye pain—Capecitabine—esophageal cancer	0.000552	0.00787	CcSEcCtD
Azelastine—Ulcer—Methotrexate—esophageal cancer	0.00054	0.0077	CcSEcCtD
Azelastine—Increased appetite—Capecitabine—esophageal cancer	0.00053	0.00756	CcSEcCtD
Azelastine—Atrial fibrillation—Capecitabine—esophageal cancer	0.000526	0.0075	CcSEcCtD
Azelastine—Arthritis—Capecitabine—esophageal cancer	0.000513	0.00731	CcSEcCtD
Azelastine—Conjunctivitis—Cisplatin—esophageal cancer	0.000506	0.00722	CcSEcCtD
Azelastine—Face oedema—Capecitabine—esophageal cancer	0.000481	0.00686	CcSEcCtD
Azelastine—Urinary retention—Capecitabine—esophageal cancer	0.000474	0.00676	CcSEcCtD
Azelastine—Mouth ulceration—Methotrexate—esophageal cancer	0.000462	0.00659	CcSEcCtD
Azelastine—Visual impairment—Cisplatin—esophageal cancer	0.00045	0.00643	CcSEcCtD
Azelastine—Nasopharyngitis—Capecitabine—esophageal cancer	0.000445	0.00635	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000439	0.00627	CcSEcCtD
Azelastine—Eye disorder—Cisplatin—esophageal cancer	0.000437	0.00623	CcSEcCtD
Azelastine—Flushing—Cisplatin—esophageal cancer	0.000434	0.00619	CcSEcCtD
Azelastine—Asthma—Capecitabine—esophageal cancer	0.000431	0.00614	CcSEcCtD
Azelastine—Bronchospasm—Capecitabine—esophageal cancer	0.000423	0.00604	CcSEcCtD
Azelastine—Bronchitis—Capecitabine—esophageal cancer	0.000414	0.0059	CcSEcCtD
Azelastine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0004	0.00571	CcSEcCtD
Azelastine—Weight increased—Capecitabine—esophageal cancer	0.000392	0.00559	CcSEcCtD
Azelastine—Vision blurred—Cisplatin—esophageal cancer	0.000384	0.00547	CcSEcCtD
Azelastine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000383	0.00546	CcSEcCtD
Azelastine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000378	0.00539	CcSEcCtD
Azelastine—Conjunctivitis—Capecitabine—esophageal cancer	0.000373	0.00532	CcSEcCtD
Azelastine—Malaise—Cisplatin—esophageal cancer	0.000367	0.00523	CcSEcCtD
Azelastine—Haematuria—Capecitabine—esophageal cancer	0.000366	0.00522	CcSEcCtD
Azelastine—Epistaxis—Capecitabine—esophageal cancer	0.000362	0.00516	CcSEcCtD
Azelastine—Myalgia—Cisplatin—esophageal cancer	0.000346	0.00494	CcSEcCtD
Azelastine—Rhinitis—Capecitabine—esophageal cancer	0.000345	0.00493	CcSEcCtD
Azelastine—Anxiety—Cisplatin—esophageal cancer	0.000345	0.00492	CcSEcCtD
Azelastine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000343	0.00489	CcSEcCtD
Azelastine—Discomfort—Cisplatin—esophageal cancer	0.000342	0.00488	CcSEcCtD
Azelastine—Pharyngitis—Capecitabine—esophageal cancer	0.000342	0.00488	CcSEcCtD
Azelastine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000332	0.00474	CcSEcCtD
Azelastine—Visual impairment—Capecitabine—esophageal cancer	0.000332	0.00474	CcSEcCtD
Azelastine—Infection—Cisplatin—esophageal cancer	0.00033	0.00471	CcSEcCtD
Azelastine—Tachycardia—Cisplatin—esophageal cancer	0.000324	0.00462	CcSEcCtD
Azelastine—Eye disorder—Capecitabine—esophageal cancer	0.000322	0.00459	CcSEcCtD
Azelastine—Asthma—Methotrexate—esophageal cancer	0.00032	0.00457	CcSEcCtD
Azelastine—Flushing—Capecitabine—esophageal cancer	0.00032	0.00456	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000303	0.00432	CcSEcCtD
Azelastine—Paraesthesia—Cisplatin—esophageal cancer	0.000298	0.00425	CcSEcCtD
Azelastine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000298	0.00425	CcSEcCtD
Azelastine—Dyspnoea—Cisplatin—esophageal cancer	0.000296	0.00422	CcSEcCtD
Azelastine—Dysgeusia—Capecitabine—esophageal cancer	0.000294	0.00419	CcSEcCtD
Azelastine—Back pain—Capecitabine—esophageal cancer	0.00029	0.00414	CcSEcCtD
Azelastine—Pain—Cisplatin—esophageal cancer	0.000284	0.00405	CcSEcCtD
Azelastine—Vision blurred—Capecitabine—esophageal cancer	0.000283	0.00403	CcSEcCtD
Azelastine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000278	0.00397	CcSEcCtD
Azelastine—Conjunctivitis—Methotrexate—esophageal cancer	0.000278	0.00396	CcSEcCtD
Azelastine—Feeling abnormal—Cisplatin—esophageal cancer	0.000274	0.0039	CcSEcCtD
Azelastine—Haematuria—Methotrexate—esophageal cancer	0.000272	0.00389	CcSEcCtD
Azelastine—Malaise—Capecitabine—esophageal cancer	0.000271	0.00386	CcSEcCtD
Azelastine—Epistaxis—Methotrexate—esophageal cancer	0.00027	0.00384	CcSEcCtD
Azelastine—Vertigo—Capecitabine—esophageal cancer	0.00027	0.00384	CcSEcCtD
Azelastine—Palpitations—Capecitabine—esophageal cancer	0.000265	0.00378	CcSEcCtD
Azelastine—Body temperature increased—Cisplatin—esophageal cancer	0.000263	0.00374	CcSEcCtD
Azelastine—Cough—Capecitabine—esophageal cancer	0.000262	0.00373	CcSEcCtD
Azelastine—Hypertension—Capecitabine—esophageal cancer	0.000259	0.00369	CcSEcCtD
Azelastine—Chest pain—Capecitabine—esophageal cancer	0.000255	0.00364	CcSEcCtD
Azelastine—Myalgia—Capecitabine—esophageal cancer	0.000255	0.00364	CcSEcCtD
Azelastine—Pharyngitis—Methotrexate—esophageal cancer	0.000255	0.00363	CcSEcCtD
Azelastine—Anxiety—Capecitabine—esophageal cancer	0.000254	0.00363	CcSEcCtD
Azelastine—Discomfort—Capecitabine—esophageal cancer	0.000252	0.0036	CcSEcCtD
Azelastine—Dry mouth—Capecitabine—esophageal cancer	0.00025	0.00356	CcSEcCtD
Azelastine—Visual impairment—Methotrexate—esophageal cancer	0.000247	0.00353	CcSEcCtD
Azelastine—Confusional state—Capecitabine—esophageal cancer	0.000247	0.00352	CcSEcCtD
Azelastine—Hypersensitivity—Cisplatin—esophageal cancer	0.000245	0.00349	CcSEcCtD
Azelastine—Infection—Capecitabine—esophageal cancer	0.000243	0.00347	CcSEcCtD
Azelastine—Eye disorder—Methotrexate—esophageal cancer	0.00024	0.00342	CcSEcCtD
Azelastine—Tachycardia—Capecitabine—esophageal cancer	0.000239	0.00341	CcSEcCtD
Azelastine—Asthenia—Cisplatin—esophageal cancer	0.000238	0.0034	CcSEcCtD
Azelastine—Diarrhoea—Cisplatin—esophageal cancer	0.000227	0.00324	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000223	0.00318	CcSEcCtD
Azelastine—Paraesthesia—Capecitabine—esophageal cancer	0.00022	0.00314	CcSEcCtD
Azelastine—Dysgeusia—Methotrexate—esophageal cancer	0.000219	0.00312	CcSEcCtD
Azelastine—Dyspnoea—Capecitabine—esophageal cancer	0.000218	0.00311	CcSEcCtD
Azelastine—Back pain—Methotrexate—esophageal cancer	0.000216	0.00308	CcSEcCtD
Azelastine—Vomiting—Cisplatin—esophageal cancer	0.000211	0.00301	CcSEcCtD
Azelastine—Fatigue—Capecitabine—esophageal cancer	0.000211	0.00301	CcSEcCtD
Azelastine—Vision blurred—Methotrexate—esophageal cancer	0.00021	0.003	CcSEcCtD
Azelastine—Rash—Cisplatin—esophageal cancer	0.000209	0.00299	CcSEcCtD
Azelastine—Pain—Capecitabine—esophageal cancer	0.000209	0.00299	CcSEcCtD
Azelastine—Constipation—Capecitabine—esophageal cancer	0.000209	0.00299	CcSEcCtD
Azelastine—Dermatitis—Cisplatin—esophageal cancer	0.000209	0.00298	CcSEcCtD
Azelastine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000207	0.00296	CcSEcCtD
Azelastine—Feeling abnormal—Capecitabine—esophageal cancer	0.000202	0.00288	CcSEcCtD
Azelastine—Malaise—Methotrexate—esophageal cancer	0.000201	0.00287	CcSEcCtD
Azelastine—Vertigo—Methotrexate—esophageal cancer	0.000201	0.00286	CcSEcCtD
Azelastine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0002	0.00286	CcSEcCtD
Azelastine—Nausea—Cisplatin—esophageal cancer	0.000197	0.00281	CcSEcCtD
Azelastine—Cough—Methotrexate—esophageal cancer	0.000195	0.00278	CcSEcCtD
Azelastine—Abdominal pain—Capecitabine—esophageal cancer	0.000194	0.00276	CcSEcCtD
Azelastine—Body temperature increased—Capecitabine—esophageal cancer	0.000194	0.00276	CcSEcCtD
Azelastine—Chest pain—Methotrexate—esophageal cancer	0.00019	0.00271	CcSEcCtD
Azelastine—Myalgia—Methotrexate—esophageal cancer	0.00019	0.00271	CcSEcCtD
Azelastine—Discomfort—Methotrexate—esophageal cancer	0.000188	0.00268	CcSEcCtD
Azelastine—Confusional state—Methotrexate—esophageal cancer	0.000184	0.00262	CcSEcCtD
Azelastine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000182	0.0026	CcSEcCtD
Azelastine—Infection—Methotrexate—esophageal cancer	0.000181	0.00258	CcSEcCtD
Azelastine—Hypersensitivity—Capecitabine—esophageal cancer	0.00018	0.00257	CcSEcCtD
Azelastine—Asthenia—Capecitabine—esophageal cancer	0.000176	0.00251	CcSEcCtD
Azelastine—Pruritus—Capecitabine—esophageal cancer	0.000173	0.00247	CcSEcCtD
Azelastine—Diarrhoea—Capecitabine—esophageal cancer	0.000168	0.00239	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000166	0.00237	CcSEcCtD
Azelastine—Paraesthesia—Methotrexate—esophageal cancer	0.000164	0.00233	CcSEcCtD
Azelastine—Dyspnoea—Methotrexate—esophageal cancer	0.000162	0.00232	CcSEcCtD
Azelastine—Somnolence—Methotrexate—esophageal cancer	0.000162	0.00231	CcSEcCtD
Azelastine—Dizziness—Capecitabine—esophageal cancer	0.000162	0.00231	CcSEcCtD
Azelastine—Fatigue—Methotrexate—esophageal cancer	0.000157	0.00224	CcSEcCtD
Azelastine—Pain—Methotrexate—esophageal cancer	0.000156	0.00222	CcSEcCtD
Azelastine—Vomiting—Capecitabine—esophageal cancer	0.000156	0.00222	CcSEcCtD
Azelastine—Rash—Capecitabine—esophageal cancer	0.000154	0.0022	CcSEcCtD
Azelastine—Dermatitis—Capecitabine—esophageal cancer	0.000154	0.0022	CcSEcCtD
Azelastine—Headache—Capecitabine—esophageal cancer	0.000153	0.00219	CcSEcCtD
Azelastine—Feeling abnormal—Methotrexate—esophageal cancer	0.00015	0.00214	CcSEcCtD
Azelastine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000149	0.00213	CcSEcCtD
Azelastine—Nausea—Capecitabine—esophageal cancer	0.000145	0.00207	CcSEcCtD
Azelastine—Body temperature increased—Methotrexate—esophageal cancer	0.000144	0.00205	CcSEcCtD
Azelastine—Abdominal pain—Methotrexate—esophageal cancer	0.000144	0.00205	CcSEcCtD
Azelastine—Hypersensitivity—Methotrexate—esophageal cancer	0.000134	0.00192	CcSEcCtD
Azelastine—Asthenia—Methotrexate—esophageal cancer	0.000131	0.00186	CcSEcCtD
Azelastine—Pruritus—Methotrexate—esophageal cancer	0.000129	0.00184	CcSEcCtD
Azelastine—Diarrhoea—Methotrexate—esophageal cancer	0.000125	0.00178	CcSEcCtD
Azelastine—Dizziness—Methotrexate—esophageal cancer	0.000121	0.00172	CcSEcCtD
Azelastine—Vomiting—Methotrexate—esophageal cancer	0.000116	0.00165	CcSEcCtD
Azelastine—Rash—Methotrexate—esophageal cancer	0.000115	0.00164	CcSEcCtD
Azelastine—Dermatitis—Methotrexate—esophageal cancer	0.000115	0.00164	CcSEcCtD
Azelastine—Headache—Methotrexate—esophageal cancer	0.000114	0.00163	CcSEcCtD
Azelastine—Nausea—Methotrexate—esophageal cancer	0.000108	0.00154	CcSEcCtD
Azelastine—HRH1—Signaling Pathways—NOTCH3—esophageal cancer	1.4e-05	8.99e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—GHRL—esophageal cancer	1.4e-05	8.99e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.4e-05	8.99e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GNG7—esophageal cancer	1.39e-05	8.94e-05	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.39e-05	8.94e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.39e-05	8.94e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.39e-05	8.93e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NOTCH2—esophageal cancer	1.39e-05	8.91e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TYMP—esophageal cancer	1.38e-05	8.86e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—FBXW7—esophageal cancer	1.38e-05	8.84e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.37e-05	8.83e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.37e-05	8.79e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CA2—esophageal cancer	1.37e-05	8.78e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GNG7—esophageal cancer	1.36e-05	8.73e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.36e-05	8.73e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.35e-05	8.65e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.35e-05	8.65e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.34e-05	8.62e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.34e-05	8.58e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.33e-05	8.57e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CYP1B1—esophageal cancer	1.31e-05	8.41e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.31e-05	8.4e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ALDH2—esophageal cancer	1.3e-05	8.38e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.3e-05	8.37e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ENO1—esophageal cancer	1.3e-05	8.37e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PSME2—esophageal cancer	1.28e-05	8.25e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PSME1—esophageal cancer	1.28e-05	8.25e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CYP1B1—esophageal cancer	1.28e-05	8.23e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GNG7—esophageal cancer	1.28e-05	8.23e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.28e-05	8.22e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ALDH2—esophageal cancer	1.27e-05	8.18e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ADH7—esophageal cancer	1.27e-05	8.16e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.27e-05	8.16e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GNG7—esophageal cancer	1.27e-05	8.16e-05	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—MYC—esophageal cancer	1.27e-05	8.13e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	1.26e-05	8.06e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.25e-05	8.01e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TPI1—esophageal cancer	1.25e-05	8.01e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTT1—esophageal cancer	1.24e-05	7.97e-05	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—EGFR—esophageal cancer	1.24e-05	7.95e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CYP19A1—esophageal cancer	1.23e-05	7.9e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TGFBR2—esophageal cancer	1.23e-05	7.9e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1.23e-05	7.88e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.22e-05	7.86e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.22e-05	7.85e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTT1—esophageal cancer	1.21e-05	7.78e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CYP1B1—esophageal cancer	1.21e-05	7.76e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CYP19A1—esophageal cancer	1.2e-05	7.74e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.2e-05	7.72e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.2e-05	7.71e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.2e-05	7.69e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.2e-05	7.68e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.19e-05	7.64e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SMAD4—esophageal cancer	1.16e-05	7.48e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.16e-05	7.47e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ENO1—esophageal cancer	1.16e-05	7.47e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.15e-05	7.39e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PSME2—esophageal cancer	1.15e-05	7.36e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PSME1—esophageal cancer	1.15e-05	7.36e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.14e-05	7.33e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.14e-05	7.33e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CYP19A1—esophageal cancer	1.14e-05	7.3e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS1—esophageal cancer	1.13e-05	7.29e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ENO1—esophageal cancer	1.13e-05	7.29e-05	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.13e-05	7.29e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.13e-05	7.27e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.13e-05	7.25e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.12e-05	7.21e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.12e-05	7.2e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.12e-05	7.19e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PSME2—esophageal cancer	1.12e-05	7.18e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PSME1—esophageal cancer	1.12e-05	7.18e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.11e-05	7.16e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.11e-05	7.15e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	1.11e-05	7.15e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.11e-05	7.12e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—HMOX1—esophageal cancer	1.1e-05	7.06e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.1e-05	7.05e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GNG7—esophageal cancer	1.08e-05	6.97e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.08e-05	6.92e-05	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—PIK3CA—esophageal cancer	1.07e-05	6.9e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ENO1—esophageal cancer	1.07e-05	6.87e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.07e-05	6.87e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMP—esophageal cancer	1.06e-05	6.84e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ENO1—esophageal cancer	1.06e-05	6.81e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.06e-05	6.81e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ABCB1—esophageal cancer	1.06e-05	6.78e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SMAD4—esophageal cancer	1.05e-05	6.77e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PSME1—esophageal cancer	1.05e-05	6.77e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PSME2—esophageal cancer	1.05e-05	6.77e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.05e-05	6.77e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PSME1—esophageal cancer	1.04e-05	6.71e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PSME2—esophageal cancer	1.04e-05	6.71e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CYP19A1—esophageal cancer	1.04e-05	6.69e-05	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—esophageal cancer	1.04e-05	6.68e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—HMOX1—esophageal cancer	1.04e-05	6.66e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.04e-05	6.65e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.02e-05	6.53e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.02e-05	6.53e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.01e-05	6.48e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1e-05	6.43e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ABCB1—esophageal cancer	9.95e-06	6.39e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	9.89e-06	6.35e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTT1—esophageal cancer	9.67e-06	6.21e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP1B1—esophageal cancer	9.65e-06	6.2e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TPI1—esophageal cancer	9.62e-06	6.18e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTO1—esophageal cancer	9.62e-06	6.18e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	9.56e-06	6.14e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	9.53e-06	6.12e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.52e-06	6.12e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—HMOX1—esophageal cancer	9.5e-06	6.11e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.32e-06	5.99e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	9.3e-06	5.97e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALDOB—esophageal cancer	9.23e-06	5.93e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.12e-06	5.86e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ABCB1—esophageal cancer	9.12e-06	5.86e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KDR—esophageal cancer	9.11e-06	5.85e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	9.09e-06	5.84e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP19A1—esophageal cancer	9.07e-06	5.83e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS1—esophageal cancer	9.06e-06	5.82e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ENO1—esophageal cancer	9.06e-06	5.82e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	9.02e-06	5.79e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PSME2—esophageal cancer	8.93e-06	5.74e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PSME1—esophageal cancer	8.93e-06	5.74e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CREBBP—esophageal cancer	8.93e-06	5.73e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GAPDH—esophageal cancer	8.88e-06	5.71e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CRABP1—esophageal cancer	8.8e-06	5.65e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	8.62e-06	5.54e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	8.58e-06	5.51e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	8.55e-06	5.49e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—HMOX1—esophageal cancer	8.48e-06	5.45e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	8.48e-06	5.45e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GNG7—esophageal cancer	8.37e-06	5.38e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.32e-06	5.35e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—HMOX1—esophageal cancer	8.28e-06	5.32e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KDR—esophageal cancer	8.25e-06	5.3e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ABCB1—esophageal cancer	8.14e-06	5.23e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—NOS3—esophageal cancer	7.99e-06	5.13e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALDH2—esophageal cancer	7.85e-06	5.04e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—HMOX1—esophageal cancer	7.8e-06	5.01e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.8e-06	5.01e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	7.78e-06	5e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	7.77e-06	4.99e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—HMOX1—esophageal cancer	7.73e-06	4.97e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	7.7e-06	4.95e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	7.65e-06	4.91e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.59e-06	4.87e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.52e-06	4.83e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ABCB1—esophageal cancer	7.49e-06	4.81e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTT1—esophageal cancer	7.46e-06	4.79e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ABCB1—esophageal cancer	7.42e-06	4.77e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	7.38e-06	4.74e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTGS2—esophageal cancer	7.31e-06	4.7e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	7.31e-06	4.7e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	7.24e-06	4.65e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CREBBP—esophageal cancer	7.2e-06	4.63e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CREBBP—esophageal cancer	7.05e-06	4.53e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	7.04e-06	4.53e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CREBBP—esophageal cancer	7.04e-06	4.52e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ENO1—esophageal cancer	6.99e-06	4.49e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.99e-06	4.49e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	6.97e-06	4.48e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	6.92e-06	4.45e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.9e-06	4.43e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PSME2—esophageal cancer	6.89e-06	4.43e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PSME1—esophageal cancer	6.89e-06	4.43e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CREBBP—esophageal cancer	6.65e-06	4.27e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	6.64e-06	4.26e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	6.62e-06	4.25e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—HMOX1—esophageal cancer	6.61e-06	4.25e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	6.52e-06	4.19e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.48e-06	4.17e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—NOS3—esophageal cancer	6.45e-06	4.14e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ABCB1—esophageal cancer	6.34e-06	4.08e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—NOS3—esophageal cancer	6.32e-06	4.06e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOS3—esophageal cancer	6.31e-06	4.05e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—NOS3—esophageal cancer	6.3e-06	4.05e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.16e-06	3.95e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CREBBP—esophageal cancer	6.1e-06	3.92e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—EP300—esophageal cancer	6.08e-06	3.91e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	6.01e-06	3.86e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—NOS3—esophageal cancer	5.95e-06	3.82e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.95e-06	3.82e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	5.9e-06	3.79e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—esophageal cancer	5.9e-06	3.79e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—esophageal cancer	5.78e-06	3.71e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—esophageal cancer	5.76e-06	3.7e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	5.76e-06	3.7e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.61e-06	3.61e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.59e-06	3.59e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	5.57e-06	3.58e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NOS3—esophageal cancer	5.46e-06	3.51e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—esophageal cancer	5.45e-06	3.5e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CREBBP—esophageal cancer	5.44e-06	3.5e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CREBBP—esophageal cancer	5.31e-06	3.41e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EP300—esophageal cancer	5.3e-06	3.4e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—esophageal cancer	5.21e-06	3.35e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.1e-06	3.28e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	5.04e-06	3.24e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CREBBP—esophageal cancer	5.01e-06	3.22e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—esophageal cancer	4.99e-06	3.21e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.96e-06	3.19e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—EP300—esophageal cancer	4.9e-06	3.15e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.9e-06	3.15e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NOS3—esophageal cancer	4.87e-06	3.13e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—EP300—esophageal cancer	4.8e-06	3.09e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EP300—esophageal cancer	4.8e-06	3.08e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.8e-06	3.08e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—EP300—esophageal cancer	4.79e-06	3.08e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NOS3—esophageal cancer	4.76e-06	3.06e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—esophageal cancer	4.62e-06	2.97e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—EP300—esophageal cancer	4.53e-06	2.91e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	4.52e-06	2.9e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—esophageal cancer	4.5e-06	2.89e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NOS3—esophageal cancer	4.48e-06	2.88e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—esophageal cancer	4.46e-06	2.86e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NOS3—esophageal cancer	4.44e-06	2.85e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—esophageal cancer	4.35e-06	2.79e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CREBBP—esophageal cancer	4.24e-06	2.72e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—esophageal cancer	4.18e-06	2.69e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—EP300—esophageal cancer	4.15e-06	2.67e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—esophageal cancer	4.1e-06	2.63e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—esophageal cancer	4.09e-06	2.63e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—esophageal cancer	4.06e-06	2.61e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	3.92e-06	2.52e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NOS3—esophageal cancer	3.8e-06	2.44e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—esophageal cancer	3.79e-06	2.44e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—EP300—esophageal cancer	3.71e-06	2.38e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—esophageal cancer	3.63e-06	2.33e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—EP300—esophageal cancer	3.62e-06	2.32e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—esophageal cancer	3.55e-06	2.28e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	3.55e-06	2.28e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	3.55e-06	2.28e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.47e-06	2.23e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—esophageal cancer	3.43e-06	2.21e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—EP300—esophageal cancer	3.41e-06	2.19e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—EP300—esophageal cancer	3.38e-06	2.17e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—esophageal cancer	3.35e-06	2.15e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.27e-06	2.1e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.07e-06	1.97e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.93e-06	1.88e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—EP300—esophageal cancer	2.89e-06	1.86e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.74e-06	1.76e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.68e-06	1.72e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.68e-06	1.72e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.52e-06	1.62e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.5e-06	1.61e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—EP300—esophageal cancer	2.23e-06	1.43e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.14e-06	1.37e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.65e-06	1.06e-05	CbGpPWpGaD
